F S&P 500
5,249.50 +3.25 (+0.06%) F Dow Jones
39,637.00 -5.00 (-0.01%) F Nasdaq
18,281.00 +26.00 (+0.14%) E-mini Russell 2000 Index Futur
2,070.00 +2.10 (+0.10%) Petróleo
78.08 -0.18 (-0.23%) Oro
2,361.00 -14.00 (-0.59%)
Equillium, Inc. (EQ)
Equillium, Inc.
2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
United States
858 240 1200
https://www.equilliumbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 44
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Daniel Mark Bradbury | Executive Chairman | 158k | N/D | 1961 |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, President, CEO & Director | 779.87k | N/D | 1966 |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior VP & COO | 553.73k | N/D | 1970 |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & Director | 571.32k | N/D | 1982 |
| Mr. Jason A. Keyes | Chief Financial Officer | N/D | N/D | 1971 |
| Penny Tom | Senior VP of Finance & Principal Accounting Officer | N/D | N/D | N/D |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development | N/D | N/D | N/D |
| Mr. Joel M. Rothman | Chief Development Officer | N/D | N/D | 1969 |
| Dr. Maple Fung M.D. | Chief Medical Officer | N/D | N/D | N/D |
Descripción
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Equillium, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
